LIF and hepatocellular carcinoma: Likewise, it gives us a hint to go further in this study, we repurposed CVB‐D as a potential drug candidate for HCC therapy, in which we not only detected LIF using mass spectrometry on biotin‐modified CVB‐D‐Probe but also found that CVB‐D may target LIF at Val145 via forming a hydrogen bond, which was demonstrated by the loss of efficacy by sh‐LIF and mutant LIFVal145 both in vitro and in vivo.